Aurora Spine Announces 100th MIS Interspinous Fusion System Sold in Italy
Aurora Spine Corporation (TSX VENTURE:ASG) announced today that the 100th ZIP™ Ultra MIS Interspinous fusion system has been sold in Italy. The first surgery in Italy occurred on September 30th, 2013.
"We are pleased with the surgeon adoption rate and our commercialization strategy of the Aurora ZIP™ Ultra MIS Interspinous Fusion System in Italy", said Trent J. Northcutt, President and CEO of Aurora Spine. We passionately believe the ZIP™ Ultra MIS implant offers a significant opportunity to provide a better spinal fusion option for doctors, hospital systems, and patients globally and that it will be a growth driver for the Company throughout Europe."
Aurora Spine will continue to be an industry leader in minimally invasive products focused on improving patient outcomes.
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the growth potential of the Aurora Spine's products. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
For more information, please contact:
Aurora Spine Corporation
President and Chief Executive Officer
Chief Financial Officer